The renal effects of ALK inhibitors

[1]  D. Planchard,et al.  ALK inhibitors in non-small cell lung cancer: the latest evidence and developments , 2016, Therapeutic advances in medical oncology.

[2]  F. Barlesi,et al.  Multicystic kidney disease: a complication of crizotinib. , 2015, Diagnostic and interventional imaging.

[3]  A. Shaw,et al.  Complex renal cysts associated with crizotinib treatment , 2015, Cancer medicine.

[4]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[5]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[6]  J. Shih,et al.  Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  D. Camidge,et al.  Crizotinib Effects on Creatinine and Non-Creatinine–Based Measures of Glomerular Filtration Rate , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  C. Dooms,et al.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Martorell,et al.  Crizotinib and renal insufficiency: a case report and review of the literature. , 2014 .

[10]  J. Baselga,et al.  A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases , 2014, Clinical Cancer Research.

[11]  A. Baron,et al.  Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib , 2014, Cancer.

[12]  C. Marquette,et al.  Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. , 2013, Lung cancer.

[13]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[14]  Youhua Liu,et al.  Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury , 2013, Kidney international.

[15]  R. Roskoski,et al.  Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. , 2013, Pharmacological research.

[16]  R. Doebele,et al.  Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer , 2012, Cancer.

[17]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[18]  S. Qin,et al.  c-Met and NF-κB-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease. , 2012, Journal of the American Society of Nephrology : JASN.

[19]  A. Levey,et al.  Estimating Equations for Glomerular Filtration Rate in the Era of Creatinine Standardization , 2012, Annals of Internal Medicine.

[20]  R. Doebele,et al.  Treating ALK-positive lung cancer—early successes and future challenges , 2012, Nature Reviews Clinical Oncology.

[21]  M. Relling,et al.  Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients , 2012, Clinical Cancer Research.

[22]  M. Tsao,et al.  c-MET as a potential therapeutic target and biomarker in cancer , 2011, Therapeutic advances in medical oncology.

[23]  J. Minna,et al.  Targeted Therapies for Lung Cancer: Clinical Experience and Novel Agents , 2011, Cancer journal.

[24]  T. Larson,et al.  Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[25]  K. Wilner,et al.  Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Jeffrey W. Clark,et al.  Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Whelan.  Guidelines on the management of renal cyst disease. , 2010, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[28]  M. Breyer,et al.  Better nephrology for mice--and man. , 2010, Kidney international.

[29]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Pao,et al.  EML4-ALK: honing in on a new target in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Eknoyan.  A clinical view of simple and complex renal cysts. , 2009, Journal of the American Society of Nephrology : JASN.

[32]  H. Mano.  Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer , 2008, Cancer science.

[33]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[34]  H. Sugimura,et al.  EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. , 2008, Lung cancer.

[35]  A. Mosharafa.  Prevalence of renal cysts in a Middle‐Eastern population: an evaluation of characteristics and risk factors , 2008, BJU international.

[36]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[37]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[38]  G. Israel,et al.  An update of the Bosniak renal cyst classification system. , 2005, Urology.

[39]  T. Fujioka,et al.  Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. , 2004, The Journal of urology.

[40]  M. Okuda,et al.  Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney , 2004, Pharmaceutical Research.

[41]  J. Murchison,et al.  The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. , 2003, Clinical radiology.

[42]  D. Govender,et al.  ALK protein expression in rhabdomyosarcomas. , 2002, Histopathology.

[43]  M. Saboorian,et al.  High dietary fat intake increases renal cyst disease progression in Han:SPRD-cy rats. , 2000, The Journal of nutrition.

[44]  S T Cochran,et al.  Cystic renal masses: accurate Bosniak classification requires adequate renal CT. , 2000, AJR. American journal of roentgenology.

[45]  O. Naderer,et al.  Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions , 1997, Antimicrobial agents and chemotherapy.

[46]  V. Gattone,et al.  Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  P. Troncoso,et al.  c-met proto-oncogene expression in benign and malignant human prostate tissues. , 1995, The Journal of urology.

[48]  A. Feller,et al.  Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis? , 1995, The Lancet.

[49]  E. Higashihara,et al.  Mediation of renal cyst formation by hepatocyte growth factor , 1994, The Lancet.

[50]  S. Pileri,et al.  Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. , 1994, Cancer research.

[51]  M. Opravil,et al.  Pyrimethamine inhibits renal secretion of creatinine , 1993, Antimicrobial Agents and Chemotherapy.

[52]  M. Koopman,et al.  Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate , 1992, The Lancet.

[53]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[54]  M. First,et al.  Effect of Trimethoprim on Serum Creatinine in Healthy and Chronic Renal Failure Volunteers , 1987, Therapeutic drug monitoring.

[55]  J. Kastrup,et al.  The effect of trimethoprim on serum creatinine. , 1985, British journal of urology.

[56]  Renato Martins,et al.  Non-small cell lung cancer. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[57]  A. Malpica,et al.  C-met proto-oncogene expression in benign and malignant human renal tissues. , 1997, The Journal of urology.

[58]  W. Chan,et al.  Large-cell anaplastic lymphoma-specific translocation in Hodgkin's disease. , 1995, Lancet.

[59]  M. Bosniak,et al.  The current radiological approach to renal cysts. , 1986, Radiology.

[60]  R. Cutler,et al.  Inhibition of renal creatinine secretion by cimetidine in humans. , 1982, Renal physiology.